Results 21 to 30 of about 10,512 (252)
Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma: Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma [PDF]
Zhongguo quanke yixuePituitary prolactinoma is a neuroendocrine disease caused by excessive pituitary prolactin-cell adenoma synthesis and prolactin secretion. The standardized diagnosis and treatment of pituitary prolactinoma in of great significance for recovering and ...
TAN Huiwen, LI Danting, YU Yerong
doaj +1 more source
Sex differences in the pituitary TGFβ1 system: the role of TGFβ1 in prolactinoma development [PDF]
, 2019 Prolactinomas are the most frequent functioning pituitary adenomas, and sex differences in tumor size, behavior and incidence have been described. These differences have been associated with earlier diagnosis in woman, as well as with serum estradiol ...
Abeledo Machado, Alejandra Inés +6 more
core +1 more source
The Turkish Journal of Pediatrics, 2022 Background. Hyperprolactinaemia refers to increased circulating prolactin and is divided into functional and pathological hyperprolactinaemia. Prolactinoma is the most common cause of severe hyperprolactinaemia. Prolactinomas are rare in children.
Tuğba Kontbay +6 more
doaj +1 more source
The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]
, 2016 Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea +3 more
core +2 more sources
AIPvariant causing familial prolactinoma [PDF]
, 2020 Pathogenic variants in the aryl hydrocarbon receptor-interacting protein (AIP) gene are increasingly recognised as a cause of familial isolated pituitary adenoma. AIP-associated tumours are most commonly growth hormone (GH) producing.
Carty, DM +7 more
core +2 more sources
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
Frontiers in Endocrinology, 2022 BackgroundProlactinoma is the most common type of pituitary tumors, and its resultant tumor occupying and hormone disturbance greatly damage the health of patients.
Kejing Zhu +10 more
doaj +1 more source
Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells [PDF]
, 2011 Involvement of the pituitary BMP system in the modulation of prolactin (PRL) secretion regulated by somatostatin analogs, including octreotide (OCT) and pasireotide (SOM230), and a dopamine agonist, bromocriptine (BRC), was examined in GH3 cells.
Inagaki, Kenichi +8 more
core +1 more source
Medicina, 2022 Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET), representing approximately half of such tumors. Dopamine agonists (DAs) have traditionally been the primary treatment for the majority of prolactinomas, with surgery considered the second line.
Warrick J. Inder, Christina Jang
openaire +3 more sources
Indian Journal of Endocrinology and Metabolism, 2011 Management of prolactinoma in pregnancy is a big challenge for the treating obstetrician as prolactin levels are normally raised in pregnancy and this creates a possibility of missing the diagnosis of prolactinoma.
Sukhwinder Kaur Bajwa +3 more
doaj +1 more source
A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology [PDF]
, 2016 Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and ...
Ansorge, Olaf +6 more
core +3 more sources